The McMaster-led meta-analysis of 57 studies encompassing over 8,000 adults across 26 countries reveals moderate test-retest reliability for structured diagnostic interviews, with notable drops for anxiety, mood, and psychotic disorders compared to substance use conditions. This observational synthesis, not an RCT, carries no declared conflicts but underscores subjectivity in symptom reporting over short intervals of 7-14 days. Beyond the reported findings, this pattern echoes the DSM-5 field trials (Regier et al., 2013, American Journal of Psychiatry, n=~2,000), which similarly documented unacceptable kappa values for many categories, a continuity the MedicalXpress coverage overlooks. A third lens from the 2020 Psychological Medicine review by Chmielewski et al. highlights how reliance on these tools in clinical trials inflates placebo responses and undermines drug approvals. Inconsistent results risk inappropriate pharmacotherapy or delayed interventions for millions, particularly as guidelines from APA and NICE treat single interviews as definitive. The coverage misses broader systemic fallout: insurance reimbursements and disability claims hinge on these diagnoses, amplifying harm in subjective domains where patient interpretation varies. Future reliability demands integration with biomarkers and longitudinal tracking rather than isolated re-administration.